Long-term use and tolerability of irbesartan for control of hypertension.

Details

Ressource 1Download: BIB_17121672F6CF.P001.pdf (204.34 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_17121672F6CF
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Long-term use and tolerability of irbesartan for control of hypertension.
Journal
Integrated Blood Pressure Control
Author(s)
Forni V., Wuerzner G., Pruijm M., Burnier M.
ISSN
1178-7104 (Electronic)
ISSN-L
1178-7104
Publication state
Published
Issued date
2011
Volume
4
Pages
17-26
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150-300 mg once daily confers a lasting effect over 24 hours, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide. Additionally and partially beyond its blood pressure-lowering effect, irbesartan reduces left ventricular hypertrophy, favors right atrial remodeling in atrial fibrillation, and increases the likelihood of maintenance of sinus rhythm after cardioversion in atrial fibrillation. In addition, the renoprotective effects of irbesartan are well documented in the early and later stages of renal disease in type 2 diabetics. Furthermore, both the therapeutic effectiveness and the placebo-like side effect profile contribute to a high adherence rate to the drug. Currently, irbesartan in monotherapy or combination therapy with hydrochlorothiazide represent a rationale pharmacologic approach for arterial hypertension and early-stage and late-stage diabetic nephropathy in hypertensive type II diabetics.
Pubmed
Open Access
Yes
Create date
07/02/2013 14:28
Last modification date
20/08/2019 12:46
Usage data